JAK2 and Alzheimer disease: Another promising topical PROTAC for AD is PJ-001 (structureundisclosed), which catalyzes the degradation of JAK2 in Jeko-1 cellswith a DC50 < 100 nM exploiting the CRBN E3 ligase.The efficacy of PJ-001, formulated as 2% and 4% O/W emulsions,was evaluated in a 2,4-dinitrofluorobenzene (DNFB)-induced mouse modelof AD.